5th Exosome Based Therapeutic Development Summit

Memo

Building on the success of the 2022 summit, the 5th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications. This year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic. This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP manufacturing of EVs for clinical applications, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization. URLs:Tickets: https://go.evvnt.com/1718731-2?pid=5569Brochure: https://go.evvnt.com/1718731-3?pid=5569 Date and Time: On Tue, Sep 5, 2023 ( 8:00 AM) - Thu, Sep 7, 2023 ( 5:00 PM) Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Drug Developer Pricing - 3 day pass (Conference + Pre-Conference Focus Day): USD 4946.00,Drug Developer Pricing - 2 day pass (Conference Only): USD 2999.00,Solution Provider Pricing - 3 day pass (Conference + Pre-Conference Focus Day): USD 6046.00,Solution Provider Pricing - 2 day pass (Conference Only): USD 3799.00,Academic Pricing - 3 day pass (Conference + Pre-Conference Focus Day): USD 4246.00,Academic Pricing - 2 day pass (Conference Only): USD 2599.00 Speakers: Alex Tendler, Chief Technology Officer, ExoProTher Medical, Atta Behfar, Founder, Rion, Ben Peacock, Head of Research, NanoFCM, Brittany Mihelich#, Senior Scientist, Astellas, Bruce Werber, Chief Executive Officer, BioXTek, Chris Paradise, Vice President, Research and Development, Rion, Christopher Locher, Chief Executive Officer, Versatope Therapeutics, Emily Baker, Director, Nonclinical Development, ArunaBio, Fatah Kashanchi, Professor, George Mason University, George Shapiro, Chief Medical Innovation Officer, OrganiCell Regenerative Medicine, Gi-hoon Nam, Chief Scientific Officer, Shiftbio, Heidi Kempinski, Chief Operating Officer, Aegle Therapeutics, Hugues Wallemacq, Chief Executive Officer, Exo Biologics, Ian White, Vice President, The American College of Regenerative Medicine, Joe Nabhan, Chief Scientific Officer, Vesigen Therapeutics, Katie Gilligan, Head of Research and Development, OmniSpirant, Kevin Hicok, Chief Operating Officer, EV Therapeutics, Kuniko Kadoya, Director, Biological Research, AbbVie, Linda Marban, CEO, Capricor Therapeutics, Lyora Aharonov, Director of Research and Development, NurExone Biologic, Maroun Khoury, Co-founder and Chief Scientific Officer, Cells for Cells, Maximiliano Kunze, Co-Founder and Chief Operating Officer, Cells For Cells, Michael Bellio, Vice President, Research and Manufacturing, Organicell Regenerative Medicine, Michael LeClaire, Senior Scientist, Capricor Therapeutics, Netta Blondheim-Shraga, Vice President - Research and Development, Brainstorm Cell Therapeutics, Phil Campbell, Research Professor, Carnegie Mellon University, Coya Therapeutics, Randolph Corteling, Chief Scientific Officer, ReNeuron, Sabine Flenady Director of Biology, StemXO, Spencer Marsh, Chief Scientific Officer, The Tiny Cargo Company, Subree Subramanian, Chief Scientific Officer, EV Therapeutics, Vinny jindal, President and Chief Executive Officer, Secretome Therapeutics